Suppr超能文献

一项随机、双盲、安慰剂对照、多中心研究,旨在评估两种剂量曲马多口腔崩解片治疗少于 2 分钟早泄的疗效和安全性。

A randomized double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of the tramadol orally disintegrating tablet for the treatment of premature ejaculation within less than 2 minutes.

机构信息

Trauma Research Department, Swedish Medical Center, Englewood, CO 80113, USA.

出版信息

Eur Urol. 2012 Apr;61(4):736-43. doi: 10.1016/j.eururo.2011.08.039. Epub 2011 Aug 30.

Abstract

BACKGROUND

Premature ejaculation (PE) is a widely observed male sexual dysfunction with a major impact on quality of life for many men and their sexual partners.

OBJECTIVE

To assess the safety of tramadol orally disintegrating tablet (ODT) (Zertane) and its efficacy in prolonging intravaginal ejaculation latency time (IELT) and improving Premature Ejaculation Profile (PEP) scores.

DESIGN, SETTING, AND PARTICIPANTS: We conducted an integrated analysis of two identical 12-wk randomized double-blind, placebo-controlled phase 3 trials across 62 sites in Europe. Healthy men 18-65 yr of age with a history of lifelong PE according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision, and an IELT ≤ 120 s were included. There were 604 intent-to-treat subjects included in the analysis.

INTERVENTION

Subjects were randomized to receive 1:1:1 placebo (n=200), 62 mg tramadol ODT (n=206), or 89 mg tramadol ODT (n=198).

MEASUREMENTS

We measured overall change and fold increase in median IELT and the mean change in all four measures of the PEP. Differences across treatment groups were analyzed using Wilcoxon rank-sum tests, analysis of variance, and chi-square analyses.

RESULTS AND LIMITATIONS

Tramadol ODT resulted in significant increases in median IELT compared with placebo; increases were 0.6 min (1.6 fold), 1.2 min (2.4 fold), and 1.5 min (2.5 fold) for placebo, 62 mg tramadol ODT, and 89 mg tramadol ODT, respectively (p<0.001 for all comparisons). Men saw significantly greater improvement in all four measures of the PEP in both doses compared with placebo (p<0.05 for all comparisons). Tramadol ODT was well tolerated; study discontinuation occurred in 0%, 1.0%, and 1.6% of subjects in placebo, 62 mg, and 89 mg tramadol ODT groups, respectively. Limitations include study inclusion for men with IELT up to 120 s.

CONCLUSIONS

On-demand 62mg tramadol ODT is an effective treatment for PE in a low and safe therapeutic dose and provides a new option for managing mild to severe PE.

摘要

背景

早泄(PE)是一种广泛观察到的男性性功能障碍,对许多男性及其性伴侣的生活质量有重大影响。

目的

评估曲马多口腔崩解片(ODT)(Zertane)的安全性及其延长阴道内射精潜伏期时间(IELT)和改善早泄概况(PEP)评分的疗效。

设计、地点和参与者:我们对欧洲 62 个地点进行的两项完全相同的 12 周随机、双盲、安慰剂对照 3 期试验进行了综合分析。纳入了符合《精神障碍诊断与统计手册》第 4 版,文本修订版(DSM-IV-TR)中终生早泄病史且 IELT≤120s 的 18-65 岁健康男性。共有 604 名意向治疗受试者纳入分析。

干预

受试者随机接受 1:1:1 安慰剂(n=200)、62mg 曲马多 ODT(n=206)或 89mg 曲马多 ODT(n=198)。

测量

我们测量了 IELT 中位数的总体变化和倍数增加,以及 PEP 的所有四个测量值的平均变化。使用 Wilcoxon 秩和检验、方差分析和卡方分析分析治疗组之间的差异。

结果和局限性

曲马多 ODT 与安慰剂相比,显著增加了 IELT 的中位数;增加分别为 0.6 分钟(1.6 倍)、1.2 分钟(2.4 倍)和 1.5 分钟(2.5 倍),分别为安慰剂、62mg 曲马多 ODT 和 89mg 曲马多 ODT(所有比较均<0.001)。与安慰剂相比,两种剂量的男性在 PEP 的所有四个测量值上均有显著改善(所有比较均<0.05)。曲马多 ODT 耐受性良好;在安慰剂、62mg 和 89mg 曲马多 ODT 组中,分别有 0%、1.0%和 1.6%的受试者停药。局限性包括纳入 IELT 长达 120s 的男性进行研究。

结论

按需 62mg 曲马多 ODT 是一种低剂量安全有效的治疗早泄的方法,为治疗轻度至重度早泄提供了新的选择。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验